Recent progress on the discovery of antiamoebic agents

Area of Science:

• Medicinal Chemistry
• Parasitology
• Infectious Diseases

Background:

• Amoebiasis, caused by Entamoeba histolytica, is a significant human parasitic infection.
• Existing antiamoebic treatments have limitations, necessitating the development of new therapeutic agents.
• Heterocyclic compounds have shown promise as inhibitors of Entamoeba histolytica.

Purpose of the Study:

• To review and summarize recent advancements in heterocyclic antiamoebic agents.
• To consolidate data on Entamoeba histolytica inhibitors from 2011 to 2016.
• To identify trends and potential leads for novel antiamoebic drug discovery.

Main Methods:

• Literature review of scientific publications and patents.
• Categorization of antiamoebic agents based on heterocyclic scaffolds.
• Analysis of reported in vitro and in vivo antiamoebic activities.

Main Results:

• A diverse range of heterocyclic scaffolds were investigated for antiamoebic activity.
• Several classes of compounds demonstrated moderate to significant inhibition of Entamoeba histolytica.
• The data highlights specific structural features associated with enhanced antiamoebic efficacy.

Conclusions:

• Heterocyclic chemistry remains a fertile area for the development of novel antiamoebic drugs.
• Continued research is crucial to identify ideal compounds for treating amoebiasis.
• This review provides a valuable resource for researchers in the field of antiamoebic drug discovery.